Showing results (1-10 of 660) with videos related to
Sort By:
Pageof 66
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewL Khoja, D Day, T Wei-Wu Chen, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2015
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsT W Chen, A R Razak, P L Bedard, et al.ESMO Open|July 23, 2024
Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I studyA Algazi, K P Papadopoulos, F Tsai, et al.Oral Oncology|May 29, 2020
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neckD Day, A Prawira, A Spreafico, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2001
Impact of the media and the internet on oncology: survey of cancer patients and oncologists in CanadaX Chen, L L SiuAnnals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescriptionI Brana, L L SiuCurrent Medicinal Chemistry. Anti-Cancer Agents|December 8, 2004
An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agentsM Agulnik, L L SiuBritish Journal of Cancer|March 10, 2005
State-of-the-art management of nasopharyngeal carcinoma: current and future directionsM Agulnik, L L SiuSeminars in Urologic Oncology|February 1, 1997
Other chemotherapy regimens including mitoxantrone and suraminL L Siu, M J MooreSupportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 16, 1998
Use of mesna to prevent ifosfamide-induced urotoxicityL L Siu, M J MoorePageof 66